Marlys Fassett is a Dermatology physician affiliated with University of California, San Francisco. OpenAlex indexes 37 publications with 4,318 citations (h-index 18). By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1701 Divisadero St Fl 3
Ucsf Dermatology
San Francisco, CA 941153011
Telephone
415-353-7800Registry record last updated 6 Apr 2015.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20252 payments
- Galderma Laboratories, L.P.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
38.2%Corticosteroid28.8%Triamcinolone Acetonide74%Desoximetasone27%Part D<11 patientsInterleukin-4 Receptor alpha Antagonist9.4%Dupixent Syringe100%Part D<11 patientsSensory organs
20.6%Corticosteroid20.6%Clobetasol Propionate66%Betamethasone Dipropionate34%Part D<11 patientsAnti-infectives
15.9%Azole Antifungal15.9%Ketoconazole100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2023 per NIH RePORTER. The latest:
- Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
University of California, San Francisco
FY2023$177,498K08AR074556 - Illuminating IL-31-producing cells in allergic skin disease
University of California, San Francisco
FY2023$161,500R03AR082948 - Interleukin-31 at the neuroimmune interface of pruritus and dermatitis
University of California, San Francisco
FY2022$177,498K08AR074556
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”